Below are the most recent publications written about "Paclitaxel" by people in Profiles.
-
Thangavel K, Lakshmikuttyamma A, Thangavel C, Shoyele SA. CD44-targeted, indocyanine green-paclitaxel-loaded human serum albumin nanoparticles for potential image-guided drug delivery. Colloids Surf B Biointerfaces. 2022 Jan; 209(Pt 1):112162.
-
Sato K, Padgaonkar AA, Baker SJ, Cosenza SC, Rechkoblit O, Subbaiah DRCV, Domingo-Domenech J, Bartkowski A, Port ER, Aggarwal AK, Ramana Reddy MV, Irie HY, Reddy EP. Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease. Nat Commun. 2021 08 03; 12(1):4671.
-
Boisen MM, Lesnock JL, Richard SD, Beriwal S, Kelley JL, Zorn KK, Edwards RP. Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer. Int J Gynecol Cancer. 2016 May; 26(4):626-31.
-
Yue X, Zhao P, Wu K, Huang J, Zhang W, Wu Y, Liang X, He X. GRIM-19 inhibition induced autophagy through activation of ERK and HIF-1a not STAT3 in Hela cells. Tumour Biol. 2016 Jul; 37(7):9789-96.
-
Abu-Khalaf MM, Baumgart MA, Gettinger SN, Doddamane I, Tuck DP, Hou S, Chen N, Sullivan C, Lezon-Geyda K, Zelterman D, Hatzis C, Deshpande H, Digiovanna MP, Azodi M, Schwartz PE, Harris LN. Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors. Cancer. 2015 Jun 1; 121(11):1817-26.
-
Zinner RG, Obasaju CK, Spigel DR, Weaver RW, Beck JT, Waterhouse DM, Modiano MR, Hrinczenko B, Nikolinakos PG, Liu J, Koustenis AG, Winfree KB, Melemed SA, Guba SC, Ortuzar WI, Desaiah D, Treat JA, Govindan R, Ross HJ. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2015 Jan; 10(1):134-42.
-
Cheng H, Bai Y, Sikov W, Sinclair N, Bossuyt V, Abu-Khalaf MM, Harris LN, Rimm DL. Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab. BMC Cancer. 2014 May 08; 14:326.
-
Krivak TC, Lele S, Richard S, Secord AA, Leath CA, Brower SL, Tian C, Moore RG. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer. Am J Obstet Gynecol. 2014 Jul; 211(1):68.e1-8.
-
Chang B, Sokhn J, James E, Abu-Khalaf M. Prolonged progression-free survival in a patient with triple-negative breast cancer metastatic to the liver after chemotherapy and local radiation therapy. Clin Breast Cancer. 2014 Apr; 14(2):e61-4.
-
Corben AD, Abi-Raad R, Popa I, Teo CH, Macklin EA, Koerner FC, Taghian AG, Brachtel EF. Pathologic response and long-term follow-up in breast cancer patients treated with neoadjuvant chemotherapy: a comparison between classifications and their practical application. Arch Pathol Lab Med. 2013 Aug; 137(8):1074-82.